Vycor Medical, Inc. reported a decline in financial performance for the second quarter of 2026, with total revenue of $418,264, down 16% from $496,353 in the same period of 2025. For the first half of 2026, revenue also decreased by 6% to $876,804 compared to $932,731 in the prior year. The company's gross profit for the second quarter was $344,445, reflecting a 17% decrease from $415,271 in the previous year. The operating income for the quarter was $6,851, a significant drop from $51,146 in the second quarter of 2025, while the net loss for the quarter was $(22,288), compared to a net income of $23,887 in the same period last year.
The decline in revenue was primarily attributed to a 17% decrease in sales from Vycor Medical's product line, which generated $401,224 in the second quarter, with the drop largely stemming from international markets. In contrast, NovaVision, the company's other segment, saw a 17% increase in revenue to $17,040, driven by improved performance in its rehabilitation therapy services. The gross margin for Vycor Medical remained stable at 82%, while NovaVision's gross margin improved to 101% due to a reversal of prior depreciation over-accumulation.
Operationally, Vycor Medical's total assets decreased to $813,174 as of June 30, 2026, down from $830,420 at the end of 2025. The company reported a working capital deficiency of $4,294,543, which includes significant related party liabilities. The total liabilities increased to $5,064,398, compared to $4,917,299 at the end of the previous fiscal year. The company’s cash position improved, with cash at the end of the second quarter rising to $158,907 from $86,982 at the end of 2025, primarily due to better cash flow from operating activities.
In terms of strategic developments, Vycor Medical is focused on reducing operating losses and may seek additional equity or debt funding to support its operations. The company has been exploring partnerships and licensing opportunities, particularly for its NovaVision segment, to enhance distribution and market reach. The management has indicated that while they are executing a plan to achieve revenue growth, there is substantial doubt regarding the company's ability to continue as a going concern without additional funding.
Looking ahead, Vycor Medical aims to increase market penetration in the U.S. and expand internationally, while continuing to develop new products that meet market demands. The company is also considering various strategic alternatives for its NovaVision division, which may include partnerships or potential mergers. However, the management cautioned that the future performance is subject to various risks and uncertainties, and actual results may differ from current expectations.
About VYCOR MEDICAL INC
Vycor Medical, Inc. develops and markets medical devices for neurosurgery, including the ViewSite Brain Access System, and provides non-invasive vision rehabilitation therapies through NovaVision. Serving hospitals and patients worldwide, it offers minimally invasive surgical tools and digital health therapies. The company leverages regulatory approvals, innovative product development, and strategic partnerships to address neurological and vision impairment markets. Its business model focuses on device sales and therapy services in healthcare.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov